-
1
المؤلفون: Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo
المصدر: Nature Medicine. 27:301-309
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Surrogate endpoint, Melanoma, medicine.medical_treatment, Ipilimumab, General Medicine, Immunotherapy, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Targeted therapy, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Nivolumab, business, Neoadjuvant therapy, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::826ffd3ff8235e1e6c027f5367069a0cTest
https://doi.org/10.1038/s41591-020-01188-3Test -
2
المؤلفون: A.C.J. van Akkooi, Judith M. Versluis, Christian U. Blank, Charlotte L. Zuur, Elisa A. Rozeman, Willem M.C. Klop, Esmée P. Hoefsmit, Lindsay G Grijpink-Ongering, María Jesús González González, Sandra Adriaansz, Robyn P. M. Saw, Sydney Ch'ng, Sten Cornelissen, J Stretch, Annegien Broeks, Ton N. Schumacher, A A Torres Acosta, Hanna Eriksson, Ron M. Kerkhoven, B.A. van de Wiel, Petros Dimitriadis, Richard A. Scolyer, Oscar Krijgsman, Daniel S. Peeper, J.B.A.G. Haanen, Omgo E. Nieweg, Karolina Sikorska, Kerwin F. Shannon, Georgina V. Long, W.J. van Houdt, A.M. Menzies, H. Mallo, Irene L.M. Reijers, Andrew J. Spillane
المصدر: Nature Medicine. 27:256-263
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Melanoma, Phases of clinical research, Ipilimumab, General Medicine, medicine.disease, General Biochemistry, Genetics and Molecular Biology, law.invention, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adjuvant therapy, Biomarker (medicine), Nivolumab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::391917477f238f400900eee0200e3f22Test
https://doi.org/10.1038/s41591-020-01211-7Test -
3
المؤلفون: Maurits L. van Montfoort, Daniel J. Vis, Kees Hendricksen, Nick van Dijk, Laura A. Smit, Michiel S. van der Heijden, Henk G. van der Poel, Maries van den Broek, Christian U. Blank, Annemarie Bruining, Yoni Lubeck, Lodewyk F. A. Wessels, Dennis Peters, Pia Kvistborg, Karina Silina, Ton N. Schumacher, Charlotte van Rooijen, Karolina Sikorska, Erik Hooijberg, Annegien Broeks, Bas W.G. van Rhijn, Alberto Gil-Jimenez, Jeantine M de Feijter, Thierry N. Boellaard
المساهمون: University of Zurich, van der Heijden, Michiel S, Graduate School
المصدر: Nature medicine, 26(12), 1839-1844. Nature Publishing Group
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, 610 Medicine & health, Ipilimumab, 10263 Institute of Experimental Immunology, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, 1300 General Biochemistry, Genetics and Molecular Biology, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, CTLA-4 Antigen, Stage (cooking), Adverse effect, Aged, Neoplasm Staging, business.industry, Antibodies, Monoclonal, General Medicine, Immunotherapy, Middle Aged, Clinical trial, Nivolumab, 030104 developmental biology, 030220 oncology & carcinogenesis, Monoclonal, 570 Life sciences, biology, Female, Urothelium, business, medicine.drug
وصف الملف: 2020_van_Dijk_Nat_Med.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0413d513e2c90df2d190163c39a4236dTest
http://www.scopus.com/inward/record.url?scp=85092396181&partnerID=8YFLogxKTest -
4
المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology
المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test -
5
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
6
المؤلفون: Jan Willem B. de Groot, Djura Piersma, John B. A. G. Haanen, Astrid A M van der Veldt, Alfonsus J. M. van den Eertwegh, Christian U. Blank, Gerard Vreugdenhil, Ellen Kapiteijn, Esther Bastiaannet, Monique K van der Kooij, Miranda P Dierselhuis, Marye J Boers-Sonderen, Karijn P M Suijkerbuijk, Albert J. ten Tije, Franchette W P J van den Berkmortel, Marjolein J A L Wetzels, Maureen J.B. Aarts, Rozemarijn S. van Rijn, Michel W.J.M. Wouters, Geke A. P. Hospers
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS)
المصدر: van der Kooij, M K, Wetzels, M J A L, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, Dierselhuis, M P, de Groot, J W B, Hospers, G A P, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Haanen, J B A G, van den Eertwegh, A J M, Bastiaannet, E & Kapiteijn, E 2020, ' Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response ', Cancers, vol. 12, no. 8, 2072, pp. 1-15 . https://doi.org/10.3390/cancers12082072Test
Cancers, 12(8):2072, 1-15. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 12, 8
Cancers, 12
Cancers
Cancers, 12(8):2072. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 12(8):2072, 1-15. MDPI AG
Cancers, Vol 12, Iss 2072, p 2072 (2020)
Cancers, 12(8). MDPIمصطلحات موضوعية: Neuroblastoma RAS viral oncogene homolog, advanced melanoma, young adults, Cancer Research, medicine.medical_specialty, AYA, microbiome, open-label, lcsh:RC254-282, survival, Article, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, METASTATIC MELANOMA, Cumulative incidence, adolescents, Young adult, ipilimumab, Adverse effect, PEMBROLIZUMAB, risk, nivolumab, business.industry, MUTATIONS, prospective nation-wide data, Melanoma, Hazard ratio, clinical audit, Cancer, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, targeted therapy, humanities, Clinical trial, BRAF mutation, Oncology, 030220 oncology & carcinogenesis, choice chemotherapy, outcome research, business, checkpoint inhibitors
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de7e43ad335ec2975ce6222cf027b69dTest
https://doi.org/10.3390/cancers12082072Test -
7
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
8
المؤلفون: Roland Van Velthoven, Sandrine Marreaud, Peter F.A. Mulders, Christian U. Blank, Sylvie Rottey, Sandra Collette, Johannes V. Van Thienen, Laurence Collette, Thomas Powles, Axel Bex, Lori Wood, Harm H.H.E. Van Melick, Jean Baptiste Lattouf, Igle J. de Jong, John B. A. G. Haanen, John Wagstaff, Bertrand Tombal, Michael A.S. Jewett, M.P. Laguna, Maureen J.B. Aarts
المساهمون: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Bex, Axel, van Thienen, Johannes V., Blank, Christian U., Haanen, John Netherlands Canc Inst, Amsterdam, Netherlands, Mulders, Peter Catholic Univ Nijmegen, Dept Urol, Nijmegen, Netherlands, Jewett, Michael Princess Margaret Hosp, Dept Urol, Toronto, ON, Canada, Wagstaff, John Cardiff Hosp, Dept Oncol, Cardiff, S Glam, Wales, van Velthoven, Roland Inst Jules Bordet, Dept Urol, Brussels, Belgium, Laguna, Maria del Pilar Istanbul Medipol Univ, Dept Urol, Istanbul, Turkey, Wood, Lori QEII Hlth Sci Ctr, Div Med Oncol, Halifax, NS, Canada, van Melick, Harm H. E. St Antonius Hosp, Dept Urol, Nieuwegein, Netherlands, Aarts, Maureen J. Maastricht Univ, Med Ctr, Dept Oncol, Maastricht, Netherlands, Lattouf, J. B. Univ Montreal, Hosp Ctr, Dept Surg Urol, Quebec City, ON, Canada, Powles, Thomas Royal Free Hosp, Dept Oncol, London, England, Powles, Thomas Queen Mary Univ, London, England, de Jong, Igle Jan Univ Groningen, Univ Med Ctr Groningen, Dept Urol, Groningen, Netherlands, Rottey, Sylvie Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium, Tombal, Bertrand Clin Univ St Luc, Dept Urol, Brussels, Belgium, Marreaud, Sandrine, Collette, Sandra, Collette, Laurence European Org Res Treatment Canc, Dept Stat, Brussels, Belgium, Collette, Sandra Bristol Myers Squibb, Brussels, Belgium, Uluslararası Tıp Fakültesi, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
المصدر: JAMA oncology, 5 (2
Translational Cancer Research
JAMA oncology, 5(2), 164-170. AMER MEDICAL ASSOC
JAMA oncology, Vol. 5, no. 2, p. 164-170 (2019)
Jama Oncology, 5, 164-170
Jama Oncology, 5, 2, pp. 164-170
JAMA Oncology, 5(2), 164-170. American Medical Associationمصطلحات موضوعية: Male, Cancer Research, Time Factors, medicine.medical_treatment, urologic and male genital diseases, Nephrectomy, law.invention, 0302 clinical medicine, TARGETED THERAPY, Randomized controlled trial, law, Renal cell carcinoma, Clinical endpoint, Sunitinib, 030212 general & internal medicine, Original Investigation, Hazard ratio, Cytoreduction Surgical Procedures, Middle Aged, RADICAL NEPHRECTOMY, CANCER, Kidney Neoplasms, Neoadjuvant Therapy, Progression-Free Survival, Europe, Editorial Commentary, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Disease Progression, SURVIVAL, Female, Erratum, medicine.drug, medicine.medical_specialty, Canada, RESECTION, Urology, Antineoplastic Agents, PLANNED NEPHRECTOMY, Drug Administration Schedule, 03 medical and health sciences, MORBIDITY, All institutes and research themes of the Radboud University Medical Center, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Radiology, Nuclear Medicine and imaging, Progression-free survival, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, business.industry, MORTALITY, Généralités, medicine.disease, EFFICACY, Clinical trial, INTERFERON-ALPHA, business
وصف الملف: 1 full-text file(s): application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f60e0899118a89e59904c695dfaed4cTest
https://cris.maastrichtuniversity.nl/en/publications/30d5247a-a32b-4965-a17b-ec5771831809Test -
9
المؤلفون: Piotr Rutkowski, Wilson H. Miller, Ivana Krajsová, Christian U. Blank, Paola Queirolo, Ana Arance, Paul Lorigan, Mario Mandalà, Geke A. P. Hospers, Bart Neyns, Jacob Schachter, Vanna Chiarion Sileni, James Larkin, Martina Makrutzki, Enrique Espinosa, Alexander Guminski, Margarita Donica, Axel Hauschild, Gabriela Liszkay, Marta Nyakas, Michele Del Vecchio, Paolo A. Ascierto, Claus Garbe, Helen Gogas, Michael P. Brown
المساهمون: Clinical sciences, Medical Oncology, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS)
المصدر: European Journal of Cancer, 107, 175-185. ELSEVIER SCI LTD
مصطلحات موضوعية: 0301 basic medicine, Oncology, safety, Cancer Research, medicine.medical_specialty, Dacarbazine, Population, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, METASTATIC MELANOMA, BRAF(V600) mutation, Vemurafenib, education, Cobimetinib, Medicine(all), education.field_of_study, business.industry, Melanoma, medicine.disease, Clinical trial, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Prognostic scoring system, business, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4770200b8acfba16c98dc5dbd5caf591Test
https://doi.org/10.1016/j.ejca.2018.11.018Test -
10
المؤلفون: Christian U. Blank, Mario Mandalà, Caroline Robert, Rutger H. T. Koornstra, Shahneen Sandhu, Susana Puig, Piotr Rutkowski, Ralf Gutzmer, Andrew M. Haydon, Andrey Meshcheryakov, Anna Maria Di Giacomo, Clemens Krepler, Victoria Atkinson, Leonel Hernandez-Aya, Adnan Khattak, James Larkin, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Alexander M.M. Eggermont, Georgina V. Long, Michal Kicinski, Dirk Schadendorf, Alexander C.J. van Akkooi, Nageatte Ibrahim, S. Dalle, Paolo A. Ascierto, Stefan Suciu, Rahima Jamal, Sandrine Marreaud, Paul Lorigan
المصدر: Journal of Clinical Oncology, 39, 8, pp. 944-946
Journal of Clinical Oncology, 39, 944-946مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, MEDLINE, Medizin, Pembrolizumab, Adjuvant therapy, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], Text mining, Clinical trials, Internal medicine, Recurrence free survival, Medicine, Staging systems, Risk of relapse, Metastatic relapse, business.industry, Melanoma, Stage at diagnosis, medicine.disease, Clinical trial, Hormonal therapy, pembrolizumab, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c843a2657530330474a766f083b07e20Test
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102657696Test